Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
The New England Journal of Medicine|March 16, 2012
Placebo-controlled trial of oral laquinimod for multiple sclerosisGiancarlo Comi, Douglas Jeffery, Ludwig Kappos, et al.Multiple Sclerosis and Related Disorders|September 27, 2019
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studiesJudith Haas, Douglas Jeffery, Diego Silva, et al.Current Medical Research and Opinion|August 15, 2009
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman, Bruce Cohen, Suhayl Dhib-Jalbut, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 14, 2013
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damageMassimo Filippi, Maria A Rocca, Elisabetta Pagani, et al.BMJ Open|October 21, 2020
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head studyHelmut Butzkueven, Stephanie Licata, Douglas Jeffery, et al.Therapeutic Advances in Neurological Disorders|February 23, 2011
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyBernard Uitdehaag, Cris Constantinescu, Peter Cornelisse, et al.The Journal of Biological Chemistry|October 4, 2005
Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikreinJie Tang, Christine Luong Yu, Steven R Williams, et al.Journal of Neurology|March 19, 2013
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND studyChristian Lampl, Stefan Nagl, Barry Arnason, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosisDiego Cadavid, Jeffrey A Cohen, Mark S Freedman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 29, 2011
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trialDouglas S Goodin, Hans-Peter Hartung, Paul O'Connor, et al.Pageof 3